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Metastatic breast cancer represents a diagnostic and therapeutic challenge due to tumor heterogeneity and to various physiological
barriers that hinder drug delivery to themetastatic sites. To overcome these limitations, nanoformulated drugs have been developed
and tested in preclinical studies, and few of them have been successfully translated into clinical practice. In particular, liposomal
anthracyclines and nanoformulated albumin-bound paclitaxel have revealed an improved therapeutic index when compared to
conventional chemotherapy, with significant reduction of drugs toxicity. Several strategies for nanoparticles engineering have
more recently been explored to increase selectivity for tumor cells and to reach poorly accessible metastatic districts. Targeted
nanoparticles, directed toward tumor markers and tissue-specific metastases, may provide effective devices in case of low-
vascularized and small-sizedmetastases, thus paving the way for a real change in the natural history ofmetastatic disease. A number
of targets have been identified and exploited for surface functionalization of different types of nanoparticles, which are currently
undergoing preclinical studies. The aim of this review is to provide an overview of current nanotechnology applied to metastatic
breast cancer diagnosis and treatment. Promising results encourage an upcoming translation of this research into clinical practice
for an effective management of the disease in the near future.
1. Introduction
Metastatic breast cancer (MBC) is a major cause of cancer-
related death among women in developed countries [1].
In recent years, some distinct biological portraits of breast
cancer, characterized by different biomolecular profiles,
behaviours, and clinical courses, have been described, and
breast cancer has been defined as a heterogeneous disease
[2, 3]. In this scenario, targeted therapy toward specific
cellular receptors has gained a central role in breast cancer
management, showing strongly improved clinical outcomes
compared to older chemotherapy regimens. A paradigm of
this concept was provided by the introduction of tamoxifen
as adjuvant therapy for hormone receptors-positive breast
tumors, which has led to a fall in cancer recurrence [4].
More recently, while some chemotherapy regimens have
failed to increase patients survival, the advent of the antibody
trastuzumab has significantly improved the overall survival
for human epidermal growth factor receptor 2- (HER2-)
positive MBC, a highly aggressive cancer prone to brain
metastases [5, 6]. However, onset of resistance to trastuzumab
is not uncommon, and it leads to higher risk of local or
distant recurrence andpoor survival if therapy is not switched
to other anti-HER2 strategies [6]. Moreover, HER2-positive
cancers account for only 20–25% of breast malignancies,
while other particularly aggressive subsets still represent
an unsolved clinical challenge [7]. As an example, triple-
negative breast cancer is a particular subset of cancer highly
prone to local recurrence and distant metastases, charac-
terized by the lack of expression of the estrogen receptor,
progesterone receptor, and HER2, and no targeted therapy
is currently available. Beyond targeted therapy, conventional
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chemotherapy for MBC is generally based on anthracyclines
and taxanes. Both these drugs have excellent cytotoxic activ-
ity. As a first-line single-agent chemotherapy, doxorubicin
leads to response rates of 35–50% and reduces the risk of
death by 22% with an increased median survival up to 18
months, when compared with nonanthracycline regimens
[8, 9]. More recently, taxanes have been introduced in clinical
practice with a substantial benefit in overall survival, time to
progression, and cancer response [10]. However, despite their
significant antitumor activity, doxorubicin and taxanes are
associated with a number of severe side effects due to their
toxicity profile. The most dreaded toxicity associated with
doxorubicin is cumulative cardiotoxicity, which may lead
to irreversible cardiomyopathy and subsequent congestive
heart failure; taxanes induce significant neurotoxicity [10, 11].
These side effects are dose-dependent and mostly related
to the lack of specificity of these drugs, which also affect
healthy tissues. Severe toxicity slows down the therapeutic
index of these therapies and makes the dose reduction or
even the discontinuation of the chemotherapy necessary, with
subsequent decreased efficacy. Therefore, MBC remains a
largely incurable disease, and novel drug formulations able
to achieve specific tumor delivery and to overcome major
chemotherapy limitations are required. Moreover, various
common sites of breast cancer metastases, such as the brain,
are poorly accessible sanctuaries for cancer cells and require
smart and innovative drug delivery systems [12]. In this
context, nanotechnology represents a promising field of
research, since nanoformulation of drugs may improve their
bioavailability and allow the selective targeting of tumor
cells, with subsequent increased efficacy and lower toxicity.
Breast cancer management is the medical field with the
most extensive clinical use and themost abundant preclinical
research in nanotechnology, and more than 150 clinical trials
are currently investigating the efficacy of nanoformulated
chemotherapy [13]. The aim of this review is to provide a
state of the art in nanotechnology applied to MBC treatment,
from nanoformulated drugs already used in clinical practice
to novel functionalized nanoparticles for targeted therapy
and diagnosis. Ongoing preclinical and clinical studies are
expected to provide a significant contribution to the devel-
opment of new approaches for the management of MBC.
2. Nanotechnological Approaches for
MBC Treatment
2.1. Nano-Drug-Delivery Systems: Functional and Structural
Features. In the last decades, nanotechnology has made
many efforts to design innovative and more effective drug
delivery systems (DDS) in order to improve the phar-
macological treatment of MBC. The main goal in DDS
engineering is the achievement of an optimal therapeutic
index, which is the combined result of drug release and
efficacy, biocompatibility, and stability of the nanodevice
and physiological features of the target tissue/organ [62].
The carrier should be nontoxic and easily produced on
industrial scale to favour clinical translation [63]. Moreover,
it is crucial that the nanodrug displays the highest specificity
toward cancer cells in order to increase the delivery of active
drug to the tumor while avoiding side effects [64]. The
amount of drug molecules loaded in the carrier needs to be
adjusted and optimized in order to balance drug dosage and
compatibleDDS concentration per administration [62]. Gen-
erally, nanoparticles larger than 100 nm are easily recognized
and cleared by the reticuloendothelial system; therefore,
nanocarrier size refining is essential to provide stability in the
bloodstream and proper pharmacokinetics upon parenteral
administration [65, 66]. In the last twenty years, several
nanoparticle platforms have been developed in order to
improve pharmacokinetics and toxicity of anticancer drugs
[67]. Among the first ones, we find liposomes, which are
vesicles with a cave sphere structure constituted by single or
multiple bilayers of natural or synthetic lipids surrounding
an aqueous core. Liposomes are highly biocompatible and
biodegradable, and their size can range from few tens of
nanometers to micrometers. Since they are able to encap-
sulate hydrophilic molecules within the aqueous core and
hydrophobic agents within their lamellae, liposomes are
considered an excellent therapeutic carrier. Another kind
of highly used DDS is the albumin-bound nanoparticle
(Nab), which exploits the capability of albumin to bind and
transport hydrophobic molecules. Moreover, albumin is able
to recognize the glycoprotein receptor gp60 and mediate the
endothelial transcytosis of Nab [68, 69]. Other extensively
studied nanodevices for drug delivery include dendrimers,
protein-based nanocages, and polymeric andmetal nanopar-
ticles. Dendrimers are regularly branched macromolecules
produced starting from synthetic or natural elements such
as amino acids, sugars, or nucleotides; they can be easily
modified or conjugated with therapeutics and loaded with
drugs using the cavities of their structure [35, 70]. Protein-
based nanocages are biological nanoparticles characterized
by easy catabolism, minimal toxicity, and immunogenicity.
They are constituted by self-assembling protein subunits gen-
erally arranged in a hollow structure, which can be chemically
or genetically engineered to insert pharmaceuticals and/or
probes or to shape various and ordered functionalities, thus
enabling the realization of multifunctional nanoparticles.
The uniform cage of these nanoparticles allows the precise
control of the amount of encapsulated drugs/probes, which
is crucial in defining drug dosage. Moreover, their stability
in physiological environment avoids macromolecular aggre-
gation, thus increasing circulation time, protecting the cargo
molecule from degradation, and improving bioavailability
[71, 72]. Polymeric nanoparticles are made of biocompatible
and biodegradable polymers consisting of two ormore chains
with different hydrophobicity. Through a self-assembling
process, these chains form a core-shell structure that reduces
the interactions of the hydrophobic blocks with the aque-
ous environment. These nanoparticles show high loading
capacity and are well suited for delivery of hydrophilic or
hydrophobic small drugs ormacromolecules [36, 73]. Finally,
inert metals, such as gold, iron, and titanium, have been used
to generate multivalent and theranostic nanosystems, which
couple in a single agent both cancer therapy and diagnostics.
Indeed, thanks to their physicochemical properties, some
inorganic nanoparticles can address other biomedical appli-
cations besides the drug delivery, such as the photothermal
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therapy and the tumor imaging. They have been classified as
being inert and biocompatible; however, metal nanoparticles
retained in the organism after administration may poten-
tially cause toxicity [67]. All nano-DDS developed for MBC
management are described below and subdivided according
to their use in clinical practice or preclinical research. A
complete overview is provided in Table 1.
2.2. Nanoparticles in Clinical Use: From Liposomal Anthra-
cyclines to Nanoformulated Paclitaxel. Among the first
nanoparticles applied in medicine as drug delivery systems,
we find three anthracycline-based nanoformulations: lipo-
somal daunorubicin (DaunoXome), nonpegylated liposomal
doxorubicin (Myocet), and pegylated liposomal doxorubicin
(Doxil in USA and Caelyx in other countries). DaunoX-
ome is composed of daunorubicin entrapped in a 45 nm
unilamellar vesicle of distearoyl phosphatidylcholine (DSPC)
and cholesterol, with a half-life of 4.4 hours [27]. While
liposomal daunorubicin is widely approved for the first-
line treatment of AIDS-related Kaposi sarcoma, only scarce
literature reports on its role in MBC. In a phase I study,
DaunoXome has been administered to 16 breast cancer
patientswith a planneddose escalation from80 to 180mg/m2.
Mild cardiotoxicity was observed in 3 patients only, but
acute dose-limiting toxicity occurred as febrile neutropenia
at 120mg/m2. Moreover, only 2 patients showed objective
responses to treatment [27]. Therefore, further analyses are
required to determine the safety and efficacy of this nanofor-
mulation. Myocet is composed of doxorubicin loaded into a
180 nm vesicle of DSPC and cholesterol, with a half-life of
2-3 hours [74]. This nanoformulation is approved in combi-
nation with cyclophosphamide for the first-line treatment of
MBC in Canada and Europe. Various randomized controlled
trials have investigated Myocet efficacy and toxicity profile
compared to conventional doxorubicin. Two phase III studies
have compared nonpegylated liposomal doxorubicin versus
doxorubicin as a first-line treatment: no differences were
observed in anticancer efficacy and median survival, but
a significant reduction of cardiotoxicity was evident with
liposomal doxorubicin [18, 19]. Interestingly, nonpegylated
liposomal doxorubicin was also compared to epirubicin, a
well-known anthracycline analogue with different cardiotox-
icity compared to doxorubicin. A phase III randomized trial
showed similarly low cardiotoxicity rates, butMyocet showed
increased efficacy compared to epirubicin [20]. A meta-
analysis performed by the Cochrane Database of Systematic
Reviews on the previously described trials confirmed a
significant lower rate of cardiotoxicity with Myocet, and
also significant reduction in grade 4 neutropenia, grade > 3
nausea/vomiting, and grade > 3 diarrhoea was observed [75].
These data strongly suggest that liposomal nanoformulation
increases the therapeutic index of anthracyclines mainly by
improving the toxicity profile, although keeping substantially
comparable efficacy. The reason for decreased toxicity is that
intravenously injected liposomes hamper drug exit from the
circulation into healthy tissues, while they only extravasate at
cancer sites where endothelial capillary junctions are leaky,
thus accumulating specifically into the tumor [76]. Doxil
is a 100 nm liposomal doxorubicin coated with protective
hydrophilic surface-bound methoxypolyethylene glycol [14].
Pegylation protects liposomes from uptake by the mononu-
clear phagocyte system, thus modifying drug pharmacoki-
netics and prolonging liposomes’ blood circulation time.
Doxil half-life is higher than that of other anthracycline-
based nanoformulations (55 hours), and its biodistribution
also differs from that of conventional doxorubicin, as shown
by higher tumor concentration at lower dosage [14, 74].
Clinical trials have demonstrated again a reduced risk of
cardiotoxicity but no changes in overall survival and response
rates; moreover, Doxil led to a 48% incidence of hand-foot
syndrome, a painful erythrodysesthesia that occurs on hand
palms and feet soles [15, 16].
Beyond anthracyclines, taxanes (paclitaxel and docetaxel)
traditionally represent another mainstay of MBC treatment,
with well-established antitumor efficacy [21]. Since they are
highly hydrophobic molecules, they are commercialized in
combination with solvents (Cremophor EL and ethanol) that,
while ensuring drugs solubility, are associated with hyper-
sensitivity reactions; importantly, taxanes are associated with
neurotoxicity and enhanced axonal degeneration [77]. To
overcome these limitations, a 130 nm sized nanoformulated
albumin-bound paclitaxel (Nab-paclitaxel, Abraxane) has
been developed and subsequently approved by FDA, being
nowadays in clinical use for various solid tumors, including
MBC. After injection, Nab-paclitaxel particles benefit from
albumin-mediated enhanced active transport to accumulate
into the tumor [22]. A large number of randomized con-
trolled trials have shown that Nab-paclitaxel could be admin-
istered at a higher dose than conventional paclitaxel and
without any steroid premedication, which are normally used
before infusion of taxanes. Moreover, a lower rate of grade
4 neutropenia was observed with Nab-paclitaxel, allowing a
better therapy adherence with improved disease control and
clinical outcomes [23, 24]. Due to these significant improve-
ments in breast cancer therapy, a number of randomized
trials are currently investigatingNab-paclitaxel in association
with biologic agents used in the metastatic setting with
encouraging results in terms of reduced neurotoxicity and
higher overall response rates, although controversial findings
were observed in progression-free and overall survivals [21,
25, 26]. Certainly, further large randomized trials are required
to better clarify Nab-paclitaxel activity and optimal dosages
in different subtypes of aggressive MBC, but Nab-paclitaxel
has anticipated what we can expect from nanotechnology
introduction in clinical practice, showing global improve-
ments in both outcome and quality of life of MBC patients,
allowing shorter infusion time, avoidance of steroid premed-
ication, and potentially higher administered dosages [21, 22].
Other forms of nanoformulated paclitaxel are in phase II/III
trials [78]. A cationic liposomal paclitaxel (EndoTAG) has
been designed to enhance binding to negatively charged
endothelial cells in tumor blood vessels, with an increased
clinical benefit rate for cationic liposomal paclitaxel plus
paclitaxel, although a slight increase in grades 3-4 neutrope-
nia was observed [28]. Another nanoformulated taxane is
polymeric-micellar paclitaxel (Genexol-PM), a compound
of 20–50 nm diameter with excellent water solubility and
stability. A phase II trial performed on 41MBCs treated with
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polymeric-micellar paclitaxel as single agent has revealed an
objective response rate significantly higher if compared with
that obtained at the same dosage with Nab-paclitaxel [29].
Polymeric-micellar paclitaxel is approved in South Korea for
use in MBC [78].
3. A New Outlook from Preclinical Studies:
The Active Nanotargeting of MBC
3.1. Why and How to Target Tumor Cells? Nanotechnological
strategies have consistently improved the therapeutic index
of anthracyclines and taxanes, mainly by ameliorating their
toxicity profiles. However, improvements in clinical out-
comes are controversial, and no substantial changes in over-
all survival have been observed compared to conventional
chemotherapy in most cases. This piece of data probably
reflects the fact that nanoparticles often accumulate into the
tumor mass by enhanced permeability and retention (EPR)
effect, while hardly entering the tumor cells. The EPR effect
allows proteins larger than 30 kDa to passively extravasate
from the blood vessels into the tumor interstitial space,
thanks to the increased vascular permeability in correspon-
dence with the tumor endothelium. Indeed, during tumor
growth, neoangiogenesis is promoted in order to satisfy
the increasing oxygen demand and, at the same time, the
endothelium of the new blood vessels is tortuous, poorly
differentiated, and leaky, thus allowing molecules extrava-
sation. Moreover, solid tumors lack functional lymphatics
and are unable to eliminate extravasated nanomaterials, thus
contributing to increasing nanoparticles accumulation and
prolonged retention within the tumor [79, 80].Therefore, the
EPR effect has become one of the most exploited biological
phenomena for nanotherapeutic strategies. Nonetheless, it is
a complex process depending on many factors such as tumor
type, tumor microenvironment, and nanoparticle properties,
and it does not ensure the intracellular delivery of the drug
[79]. Certainly, the passive diffusion of nanoformulated drugs
through leaky tumor vasculature may have a prominent
role for the treatment of primary tumors with more than
100mm3 in volume; however, it remains less effective in
a metastatic setting. Metastases are only poorly accessible
to molecular or nanoparticle agents because of their small
size, high dispersion to organs, and low vascularization if
compared to primary tumors [12, 81]. As a consequence,
the EPR effect is not sufficient for proper drug nanodelivery
to these sites, and the development of effective therapies
toward metastases still remains a main challenge in cancer
treatment. In this context, nanotechnologists have developed
new systems meant to specifically target cancer cells, thus
enabling amore effective recognition of the lesion, prolonged
persistence at tumor site, and an increasing diagnostic and
therapeutic efficacy. This strategy, called “active targeting,”
involves the conjugation on the nanoparticle surface of tar-
getingmoieties, like antibodies or peptides, which specifically
bind to tumor receptors or biomarkers and subsequently
trigger nanoparticle internalization [80]. Targeted nanopar-
ticles may benefit from the EPR effect but, thanks to the
specific binding to the target, also improve tumor delivery
of therapeutics and uptake by cancer cells [67]. Liposomal
anthracyclines such as Doxil have been functionalized with
anticancer antibodies, and preclinical studies have demon-
strated improved therapeutic index and reduced side effects
when compared to original Doxil [31]. Nab-paclitaxel has
also been functionalized with the peptide Lyp-1, which
recognizes tumor lymphatics: this study has demonstrated
an increased tumor growth inhibition after treatment with
targeted Nab-paclitaxel in comparison with untargeted Nab-
paclitaxel [33]. By delivering pharmacological agents more
selectively into tumor cells, targeted nanoparticles modify
the biodistribution of therapeutic drugs and guide them
away from healthy tissues, further improving the efficacy-
toxicity ratio when compared to untargeted nanocompounds
[82]. Successful active targeting to MBC basically relies on a
thoroughunderstanding of the complex processes involved in
tumor growth, invasion, and evolution towardmetastasis and
metastasis-specific features. Certainly, a major concern is the
need of specific and reliable targets, with blown and persistent
overexpression in cancer tissues. Recently, the neuropeptide
Y1 receptor has been recognized as a novel target for breast
cancer cells, since healthy breast tissue overexpresses only
Y2 receptors. Therefore, albumin nanoparticles loaded with
doxorubicin and functionalized with PNBL-NPY, a ligand of
Y1 receptors, have been successfully used to properly address
the nanodrug to breast cancer cells [34].
3.2. Targeting the Metastatic Primary Tumor. In the past few
decades, significant progress has beenmade in understanding
the genetics and the molecular principles contributing to
malignant transformation and tumorigenesis. Gene expres-
sion profiling has been used to classify tumors, based on
molecular fingerprints that correlate with histological sub-
types and may predict the clinical outcome [83]. In partic-
ular specific molecules or pathways, either overexpressed or
dysregulated in different types of MBC, have been identified
and draw interest for targeted applications. HER2 is one of
the most commonly targeted molecules in MBC therapy,
since it is overexpressed in a large subset of aggressive
breast cancers. Antibodies that recognize HER2, such as
trastuzumab (Herceptin), represent a gold standard for the
molecularly targeted therapy [84]. In this context, a variety
of nanotherapeutic strategies based on the conjugation of
Herceptin or fragments of it to nanoparticles surface have
been explored for targeted delivery to HER2-positive breast
cancer and have led to enhanced localization and treatment
of tumors both in vitro and in vivo [45, 85–89]. Recently,
HER2-targeted nanocarriers have been intensely explored to
specifically deliver and release doxorubicin in HER2-positive
cancer cells, with enhanced anticancer activity compared to
nontargeted nanoparticles [47]. Besides HER2, more than
two-thirds of breast cancer cells display upregulation of the
estrogen receptor, which has therefore been selected as the
most important target for hormone therapy of breast cancer
[30]. Several drug delivery platforms have been successfully
engineered in order to bind other specific receptors that
are prone to endocytosis, such as the folate receptor, the
transferrin receptor-1 (TfR-1), and the epidermal growth
factor receptor (EGFR), thus enabling drugs to enter the
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cytoplasm of cancer cells and to further exert their antitu-
moral effects [41, 90–92]. Biomolecules resembling receptors
ligands or fragments of themhave been studied and produced
to be exploited in this context. This is the case for the
aminoterminal fragment of the urokinase type plasminogen
activator (uPA), which has been used as a targetingmoiety for
conjugation to the surface of iron oxide-based nanoparticle
in order to achieve specific recognition of uPA receptor-
expressing cancer cells [54]. A novel approach has been
attemptedwith smart polymeric nanoparticles functionalized
with uPA and loaded with antisense miRNAs to antagonize
miR-21, responsible for apoptosis inhibition, and miR-10b,
which induces metastatic features [39]. Interestingly, these
nanoparticles have been investigated in murine model of
triple-negative breast cancer, which is known to overexpress
uPA receptor [93], and have provided significant reduction of
tumor growth andmetastases at a very low dose (0.15mg/kg),
thus proving to be a potential novel therapeutic option for
MBC.
3.3. Targeting the Tumor Vasculature. In order to overcome
drawbacks in reaching tumor cells, various endothelial-
targeted nanodevices have been also developed [94]. These
nanoparticles either bind and kill the endothelial target,
stopping the flow of oxygen and nutrients to the tumor, or
are designed to release the drug directly within the vessel,
thus allowing it to go deep in the interstitium [95]. Several
endothelial adhesion molecules involved in migration, inva-
sion, and metastatic behaviour of cancer cells represent good
targets for nanoparticles design. Ligands immobilized on
nanoparticles surface to target tumor vasculature are the anti-
body fragment L19 and some derivatives of the RGD or NGR
peptides, which recognize the EBD domain of fibronectin
and the integrins 𝛼
2
𝛽
5
, 𝛼v𝛽3, and 𝛼5𝛽1, respectively [96, 97].
One interesting example is the multicomponent nanodevice
developed by Peiris and coworkers, which consists of iron
oxide-based nanospheres linked to a doxorubicin-loaded
liposome. This device is functionalized on both liposome
and iron oxide nanospheres with the cyclic RGD peptide
that targets the 𝛼v𝛽3 integrins and cell adhesion molecules
that mediate the metastatic site transition from tumor cell
rolling on the endothelium to firm attachment for subse-
quent extravasation and tissue invasion. The active targeting
provides the specific delivery of the nanoconstruct to tumor
neovasculature and, together with size, shape, and flexibility
of the construct, contributes to increasing the probability
of homing to micrometastases [46]. Endothelial-targeted
nanodevices have been shown to possess huge potential for
improving antitumor efficacy when compared to tumor cell-
targeted nanomedicines, and this ismostly due to the fact that
they can more easily find their final target.
3.4. Targeting SelectiveMetastatic Sites and Overcoming Barri-
ers to Cancer Reservoirs. Targeting nanomaterials specifically
to the metastatic lesions is a major challenge for translation
to clinical use. Expression profiling of metastases arising in
different tissues has revealed that gene signature frommetas-
tases can be different from that of the original neoplasm [98].
As a consequence, some targeted approaches that generate
positive effects in primary tumors could be ineffective toward
metastases. Moreover, targeting metastases depend on the
specific features of different metastatic sites. Based on the
identification of metastasis-specific features, strategies for
improving drug delivery to metastatic sites have been devel-
oped. Different targets and conjugation strategies have been
applied with respect to different types of tumor and metas-
tasis location [12]. A major concern for MBC is the higher
occurrence of brain metastases, particularly in some specific
subsets [99]. Indeed, most chemotherapeutic drugs have not
been generally considered an effective option for patients
with central nervous system metastases due to the presence
of the blood-brain barrier (BBB), which restricts the access
of high-molecular weight molecules from the vasculature
[100]. Within the BBB, the tight junctions in between brain
microvascular endothelial cells and the P-glycoprotein efflux
pumps hamper the filtration of therapeutic drugs, preventing
their penetration into the brain. Nanotechnology could be
successfully exploited to guarantee a proper addressing of
anticancer drugs into the central nervous system, and various
strategies are being investigated [101]. A multifunctional
polymeric nanotheranostic system was designed in 2014 by
Li et al. and tested in a murine model of breast cancer
metastatic to the brain. This nanocarrier demonstrated a
high permeability to BBB, with subsequent efficient release
of doxorubicin into metastatic cancer deposits and proper
gadolinium extravasation to enable an accurate imaging of
metastases on magnetic resonance (MRI) [42]. Pegylated
liposomal doxorubicin also demonstrated pharmacokinetics
and efficacy advantage over nonliposomal doxorubicin in
the treatment of an in vivo model of breast cancer brain
metastases [17].More recently, novel polymeric nanoparticles
have been attached to gadolinium, functionalized toward
HER2 or EGFR, and injected into mice bearing both lung
and breast cancers metastatic to the brain. Nanoparticles
were able to pass through the BBB and to selectively reach
metastases; moreover, when gadolinium was replaced with
selective inhibitors of HER2 or EGFR, a significant reduction
of brain metastases and a longer survival of mice were
observed [43]. Other attempts to reach brain tumors have
been carried out by active targeting of the BBB, exploiting the
overexpression of TfR-1 or apolipoprotein E (ApoE) receptors
on its surface [102, 103]; promising results suggest that this
approach could be of benefit even in MBC management.
Other intriguing progress in the field corresponds to the
targeting of bonemetastases, a common and devastating con-
sequence of breast cancer that leads to alteration of osteoblast
and osteoclast function, with resulting skeletal destruction
[104]. E-selectin-targeted nanoparticles have proven to trig-
ger bonemarrow enrichment of therapeutics, thus suggesting
a promising bone metastasis-specific device [44]. PLGA
nanoparticles loaded with antisense oligonucleotides against
osteopontin and bone sialoprotein have been successfully
used in a ratmodel of triple-negative breast cancer to demon-
strate a significant decrease in tumor bone metastasis inci-
dence and in metastases size [36]. Similar polymeric-based
biodegradable nanoformulation of siRNAs against bone-
specific genes revealed significant efficacy against migration
of breast cancer cells and osteolysis in a rat model of
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skeletal metastases [37]. In 2012, PLGA nanoparticles for
active targeting of MBC were developed by conjugation with
alendronate, a bone seekingmolecule able to bind to the bone
and reduce bone resorption. Simultaneous encapsulation of
two chemotherapeutic agents, curcumin and bortezomib,
within these nanoparticles revealed antiosteoclastogenesis
ability and significant decrease of tumor progression in an in
vivo intraosseous model of bone metastasis [40]. Other bio-
logic targets and pathways under investigation include breast
cancer-derived interleukins, cytokines, prostaglandins, inte-
grins, growth factors, and proteases that mediate cancer-
related bone resorption [105].
Another serious problem for breast cancer patients is
represented by lymph node metastases. Mitoxantrone solid
lipid nanoparticles with mean size of less than 100 nm were
prepared, characterized, and tested by subcutaneous injection
in a model of lymph node metastases [32]. Results showed
high targeting efficiency of the drug to the lymph nodes,
enhanced therapeutic effect of the antitumor agent, and
significant reduction in lymph node mean size.
Other researchers have exploited the vascular cell adhe-
sion molecule-1 (VCAM-1) as a therapeutic target against
lung metastasis of breast cancer. They have generated
hydrophobic interaction-mediated self-assembled nanopar-
ticles with succinobucol, a potent and selective VCAM-1
inhibitor, and have demonstrated improved drug bioavail-
ability and biodistribution upon nanoformulation, together
with efficacy in suppressing the lung metastasis of breast
cancer in a 4T1 breast cancer murine model [38].
3.5. Targeting the Circulating Tumor Cells. Factors that pro-
mote the infiltration, survival, and colonization of distant
organs are also attractive targets that could be used as prog-
nostic markers for guiding the therapy and/or be themselves
good therapeutic targets, to prevent metastases outgrowth.
Numerous studies have evaluated the relevance of circulating
tumor cells (CTCs) in the peripheral blood as markers of
clinical progression in breast cancer and predictive indicators
of response to therapy [106, 107]. Detecting CTCs, more
than solid organ metastases, seems to offer an effective and
reliable prediction of tumor behaviour; however, the lack of
specific and robust molecular targets is a prominent limita-
tion for this kind of approach. Galanzha and colleagues have
developed gold nanoparticles to detect circulating tumor
cells, by targeting CD44: such nanoconstructs have revealed
high sensitive and noninvasive detection of cancer cells and
their subsequent destruction by ultrasound or hyperthermia,
thus preventing metastases formation [55]. More recently,
magnetic nanogels based on magnetic nanoparticles and lin-
ear thermoresponsive polyglycerol were designed for CTCs
capturing. Nanogel surface was decorated with transferrin-
(Tf-) polyethylene glycol moieties, which provided capture of
Tf receptors-positive CTCs [59].
4. Nanoparticles for MBC Diagnosis
In the last years, many studies have been directed to the
design of new contrast agents allowing easy, reliable, and non-
invasive identification of breast cancer [108]. In this context,
the development of target-specific nanostructured contrast
agents has revealed optimal sensitivity for various imaging
techniques, from the optical imaging (fluorescence and biolu-
minescence detection) to the radionucleotide-based imaging
(positron emission tomography (PET) and computed tomog-
raphy (CT)) or MRI. Magnetic iron oxide nanoparticles are
able to enhance the T
2
-weighted negative contrast of target
tissues in MRI and, to date, they represent the prevailing
agent for breast cancer detection. Engineering the surface of
this nanodevice with specific tumor markers has led to the
generation of one of the most studied versatile platforms for
site-specific tumor imaging and localization of primary breast
cancer by MRI [50, 54, 61]. Nevertheless, the localization of
peripheral metastasis still remains a key challenge, and only a
limited number of studies have reported on this so far. Here,
we describe preclinical nanotechnological research focused
onMBCdiagnostics and provide an overviewof all developed
nanoparticles for MBC imaging in Table 2.
In an interesting study, superparamagnetic iron oxide
nanoparticles (SPIONs) have been functionalized with the
luteinizing hormone/chorionic gonadotropin (LH/CG) and
the luteinizing hormone releasing hormone (LHRH), whose
receptors are expressed in >50% of breast cancers [51]. It was
found that both types of these small (<50 nm hydrodynamic
diameter) and highly soluble nanoparticles were actively
internalized in vitro by the MDA-MB-435S breast cancer
cells after binding to their receptors. In vivo investigation
on nude mice bearing a MDA-MB-435S interscapular tumor
showed a strong accumulation of intravenously injected
LHRH-conjugated SPIONs (up to 59% of injected iron
particles) within the primary tumor but also within lung
metastases (up to 20%). MRI of breast cancers dissected
after 20-hour exposure to LHRH-conjugated SPIONs showed
that these nanoparticles were able to enhance the negative
contrast of the xenografts [52]. Multi-CRAZED magnetic
anisotropy images of isolated tissues confirmed the great
potential of LHRH-conjugated SPION as contrast agent for
lung metastases [52]. Kievit and colleagues have designed a
SPION coated with a copolymer of chitosan and polyethylene
glycol and functionalizedwith amonoclonal antibody against
human HER2/neu [60]. This neu-conjugated nanoparticle
(NP-neu) has been shown to be efficiently internalized by
neu-expressing mouse mammary carcinoma cells in vitro.
The ability of NP-neu to target MBC and to be detected
by MRI was assessed in transgenic mice that spontaneously
develop HER2/neu-positive tumors: a significant T
2
decrease
was observed at the tumor site in NP-neu-injected mice
as compared to the noninjected animals. Lung, liver, and
bone marrow metastases were also detected by histological
and cytofluorimetric assays upon NP-neu injection. Positive
Prussian blue staining of histological sections indicated the
presence of iron nanoparticles in lung and liver metastases.
This targeting effect on liver and lung by NP-neu was
further confirmed using flow cytometry analysis, which also
provided a successful detection of metastatic cancer cells in
aspirated bone marrow. Although able to selectively label
early stage micrometastases by histology or flow cytometry,
these neu-targeted nanoparticles have finally been shown to
be useless for MRI, since the micrometastases were beyond
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the spatial resolution of a 3-Tesla MRI. In the same year,
Pereis and colleagues developed a nanochain (100 nm hydro-
dynamic size) of four iron oxide nanoparticles functional-
ized with a cyclic tripeptide arginine-glycine-aspartic acid
c(RGD), for the specific targeting of vascular 𝛼v𝛽3 integrins
[48]. Fluorescence Molecular Tomography (FMT) imaging
showed that these nanochain-RGDnanoparticles (RGD-NC)
were able to actively target primary 4T1 mammary tumors in
micewithin 30minutes from intravenous injection. Targeting
of metastatic lesions by RGD-NC was also observed in vivo
and ex vivo in liver, spleen, and lungs. MRI images of the
liver in metastatic mice injected with RGD-NC showed a
significantly higher negative contrast in this organ when
compared to the preinjection contrast or to the postinjection
background signal of healthy or uninvolved regions of the
metastatic liver. Fluorescence microscopy observations of
histological sections showed the microdistribution of RGD-
NC in liver and lungs, indicating the colocalization of the
nanoparticles with both cancer cells and 𝛼v𝛽3 integrins. Most
recently, the addition of iron oxide nanoparticles to HER2-
targeted doxorubicin nanocarriers allowed for obtaining a
promising theranostic agent, suitable for both HER2-positive
breast cancer treatment and MRI diagnosis [47].
Although SPION is still the most studied nanoparticle-
based contrast agent for MRI detection of breast cancer
and its metastases, some limitations in its use are associated
with the negative contrast and the magnetic susceptibility
artefacts provided by iron oxide.Therefore, some researchers
have focused on a new class of contrast agent with positive
(T
1
-weighted) contrast ability. In this context, Na and col-
leagues have developed manganese oxide (MnO) nanopar-
ticles (25 nm diameter) functionalized with the anti-HER2
Herceptin, for MRI detection of breast cancer metastases in
mice brain [49]. After intravenous injection of Herceptin-
MnO nanoparticles, metastases were significantly enhanced
in T
1
-weighted MRI as a result of the active targeting and
the accumulation of nanoparticles into breast cancer cells.
NonfunctionalizedMnOnanoparticles were also observed to
reach the brain metastases by passing through the leaky BBB
damaged by tumor formationwithin the brain.However, only
functionalized nanoparticles were able to accumulate at the
tumor site for an extended time thanks to their interaction
with HER2.
Beyond MRI, PET imaging is indicated to complete
the staging of MBC, due to its whole-body detection of
tumor-related metabolic activity. However, its spatial reso-
lution, its specificity, and sometimes uptake of 18F-fluoro-
2-deoxy-D-glucose are not optimal [109]. Recently, Pang et
al. have demonstrated that PdCu@Au nanoparticles radiola-
beled with 64Cu and functionalized toward C-C chemokine
receptor 5, a newly identified target of triple-negative breast
cancer, were able to specifically recognize 4T1 mouse breast
cancer cells increasing by 2- to 6-fold higher recognition
compared to nontargeted nanoparticles, thus providing a
tool for highly accurate PET imaging and photothermal
treatment [53]. Interestingly, Pe´rez-Medina et al. have devel-
oped a 89Zr-labeled liposome encapsulating a near-infrared
fluorophore for both PET and optical imaging of breast
cancer. Intravenous injection of the nanotracer demonstrated
its usefulness in bimodal imaging of cancer deposits by
simultaneous PET and intraoperative optical imaging, which
is an increasing field of interest in surgical oncology [57].
Mesoporous silica nanoparticles have been also investigated
as dual-imaging tracer in murine models of metastatic breast
cancer for both PET and near-infrared optical imaging with
encouraging results regarding the targeting of both lung
metastases and tumor vasculature [56, 58].
5. Conclusions
In MBC management, conventional chemotherapy shows
major limitations in achieving a proper treatment. Although
important improvements have been obtained with nanofor-
mulated anthracyclines and paclitaxel, an accurate detection
and a satisfying treatment of the metastatic disease still
remain a key challenge. In this context, the active targeting
of malignant cells appears as a promising strategy for a
successful theranostic approach in MBC. Specific ligands or
antitumor drugs conjugated on the surface of nanoparticles
have demonstrated efficient interaction with cancer cells
and improved drug delivery to tumor sites, even through
physiological barriers. Active targeting nanostrategies are
expected to reduce toxicity and chemoresistance and to
enhance the anticancer activity. Certainly, further studies are
necessary before introducing this new class of nanodrugs
in clinical practice. However, active collaboration between
nanotechnologists and physicians has provided satisfactory
progress and should be strongly encouraged to achieve a
clinical revolution for MBC management.
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